Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML.

6557 Background: AS1411 is the most advanced aptamer in oncology clinical development. It targets nucleolin, a protein upregulated on the surface of cancer cells. Data from a phase II study of AS14...